Document Detail

Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids.
MedLine Citation:
PMID:  16305726     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Crohn's disease is a chronic inflammatory condition affecting the gastrointestinal tract. Polyunsaturated omega-3 fatty acids given orally may reduce the secretion of proinflammatory cytokines and hereby downregulate the inflammatory process. AIM: To assess the effects of enteral fatty acids, in the form of Impact Powder (Novartis, Switzerland), as adjuvant therapy to corticosteroid treatment on the proinflammatory and anti-inflammatory cytokine profiles in patients with active Crohn's disease. METHODS: The proinflammatory and anti-inflammatory cytokines were measured in plasma from 31 patients with active Crohn's disease. Patients were randomized for oral intake of omega-3 fatty acid (3-Impact Powder) or omega-6 fatty acids (6-Impact Powder). Clinical and biochemical markers of inflammation were studied at baseline and after 5 and 9 weeks. RESULTS: Within the 3-Impact Powder group, no significant changes in concentrations of interleukin-6, interferon-gamma, monocyte chemoattractant protein-1, interleukin-2, interleukin-5 and interleukin-10, whereas a significant differences in concentration of interleukin-1beta and interleukin-4 were observed during therapy. Within the 6-Impact Powder group a significant changes in concentrations of interleukin-1beta, interleukin-6, interferon-gamma, monocyte chemoattractant protein-1, interleukin-2, interleukin-4, interleukin-5 and interleukin-10 were observed. CONCLUSIONS: The 3-Impact Powder showed immunomodulatory properties and might inhibit an increase of proinflammatory cytokines in contrast to the 6-Impact Powder.
A A Nielsen; L G M Jørgensen; J N Nielsen; M Eivindson; H Grønbaek; I Vind; D M Hougaard; K Skogstrand; S Jensen; P Munkholm; I Brandslund; H Hey
Related Documents :
18788476 - Modeling studies on phospholipase a2-inhibitor complexes.
2122146 - Inhibition of hiv replication by naphthalenemonosulfonic acid derivatives and a bis nap...
8692046 - Multiple sclerosis: sunlight, diet, immunology and aetiology.
17827696 - Supercritical fluid extracts of rosemary leaves exhibit potent anti-inflammation and an...
23567836 - Efficiency of yeast in enhancement of the oxidative defense system in salt-stressed fla...
277106 - Nutritional evaluation of low-erucic-acid rapeseed oils.
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  22     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2005-11-24     Completed Date:  2006-04-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1121-8     Citation Subset:  IM    
Department of Clinical Biochemistry, Vejle Hospital, Vejle, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Body Mass Index
Crohn Disease / drug therapy*
Cytokines / antagonists & inhibitors*
Fatty Acids, Omega-3 / therapeutic use*
Fatty Acids, Omega-6 / therapeutic use*
Glucocorticoids / therapeutic use
Middle Aged
Prednisolone / therapeutic use
Reg. No./Substance:
0/Cytokines; 0/Fatty Acids, Omega-3; 0/Fatty Acids, Omega-6; 0/Glucocorticoids; 50-24-8/Prednisolone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide.
Next Document:  Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and res...